Regeneron Pharmaceuticals
30-Second Executive Brief
Executive Assessment
Regeneron Pharmaceuticals functions as an established institution within Healthcare & Life Sciences, backed by 55% sourcing coverage, with a stable competitive position.
- Maintains 2 mapped relationships across the graph
- 55% sourcing coverage across sourced relationships
- Tracked as established institution within the Healthcare & Life Sciences category
Executive Snapshot
- Strategic Role
- Established Institution
- Sourcing Coverage
- 55%
- Ecosystem Influence
- High
- Strategic Momentum
- Steady
View Methodology →
Computed live from this entity's own relationships and evidence: how many relationships carry at least one linked citation, weighted with citation recency and source type — independent of Strategic Importance, and not a prediction. Not a hand-typed number; recalculated on every read.
Coverage
- Mapped Relationships
- 2
- Technology Domains
- 5
Strategic Implications
- Central node connecting multiple strategic ecosystems
- Directly influences technology and capital flows
- Material relevance to downstream dependency mapping
Top Opportunities
Top Risks
Critical Dependencies
A biotechnology company whose higher-dose retinal drug Eylea HD grew 52% year-over-year in Q2 2026, overtaking legacy Eylea (down 45% amid biosimilar competition) for the first time as roughly 60% of combined US Eylea sales. Regeneron's Dupixent royalty/collaboration revenue (partnered with Sanofi) grew 38% in Q2 2026, and the company's approximately 50-candidate pipeline includes near-term catalysts such as an FDA decision on cemdisiran for generalized myasthenia gravis expected in November 2026.
Leading Indicators
Hiring and patent filing trends — the underlying numbers Momentum is computed from. Insider filing activity is tracked separately under Sources below.
Additional Intelligence Signals
Patent citation lineage, earnings-call mentions, and federal contract disclosures — automatically collected, not yet visible anywhere else on the site.
Earnings-call mentions
Mentioned by Intellia Therapeutics
“its ability to optimize the impact of its collaborations on its development programs, including, but not limited to, its collaboration with Regeneron Pharmaceuticals, Inc. ("Regeneron") and their co-development program for ATTR amyloidosis”
SEC 8-K exhibit (0001193125-26-215721) · May 11, 2026
Mentioned by Intellia Therapeutics
“Collaboration revenue was $7.7 million for the second quarter of 2026, compared to $14.2 million for the second quarter of 2025. The decrease is primarily due to a reduction in revenue from Regeneron.”
SEC 8-K exhibit (0001193125-26-336772) · Aug 6, 2026
Federal contract disclosures
Department of Health and Human Services — $695,741,476: IGF::OT::IGF
USAspending.gov · Sep 30, 2017
Department of Health and Human Services — $8,601,629: IGF::OT::IGF
USAspending.gov · Aug 9, 2016
Sources
Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.
Evidence
2 sources
- Regeneron — Eylea HD approved by FDA with dosing intervals up to 5 monthscompany
- BigGo Finance — Regeneron Q2 2026: Dupixent tops $6 billion, Eylea HD overtakes legacy drugnews
Latest Activity
Insider Filing Activity
Counts filing frequency only — transaction direction/size wasn't parseable from the sampled filings · sourced from SEC EDGAR · as of Sep 7, 2026
Acquisition & Investment Fit
AI-reasoned, generated only from entities already in InsightNodes's own graph — a hypothetical strategic-fit exercise, not real M&A intelligence or a signal that any deal is planned or in progress.
Relationship Map
The relationships surrounding Regeneron Pharmaceuticals — ownership, dependencies, regulation, technology and market context. Click any node to make it the new center, 2 levels deep.
Connection type
Click any node to make it the new center. Scroll to zoom, drag to pan.
The Story So Far (last 6 months)
Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.
Market Intelligence
UnverifiedCredibly-reported claims — analyst notes, sourcing citing “people familiar with the matter,” deals where the companies involved declined to comment — that haven't been officially confirmed. Kept structurally separate from the sourced evidence above; treat as a lead worth researching further, not an established fact.
Eylea HD overtaking legacy Eylea is a successful, deliberate self-cannibalization rather than a competitive loss
33% confidenceRegeneron's higher-dose Eylea HD grew 52% year-over-year to overtake legacy Eylea (down 45% amid biosimilar competition) for the first time in Q2 2026, now representing roughly 60% of combined US Eylea sales.
This is InsightNodes' own interpretive read: unlike a typical patent-cliff story where biosimilar erosion simply destroys revenue, Regeneron pre-positioned Eylea HD as a patent-protected, longer-dosing-interval successor before legacy Eylea's biosimilar exposure fully hit -- the extended dosing approval (up to 5 months) gives Eylea HD a genuine clinical differentiation from biosimilars that only replicate the original formulation, meaning this transition looks more like a successful proactive product-cycle management than a defensive scramble, a template other companies facing looming biosimilar exposure might study.
InsightNodes analysis of Regeneron Q2 2026 results · Aug 14, 2026
Regeneron Pharmaceuticals's Timeline
A sourced, dated history of Regeneron Pharmaceuticals's key moments — founding to present.
Apr 2026 · FDA approves extended Eylea HD dosing up to 5 months
The FDA approved extending Eylea HD dosing intervals up to every 20 weeks (5 months) for wet age-related macular degeneration and diabetic macular edema patients following one year of successful response.
Jul 2026 · Q2 2026: revenue up 17%, Dupixent tops $6 billion
Regeneron's Q2 2026 revenue surged 17%, with Dupixent revenue topping $6 billion and Eylea HD overtaking legacy Eylea in US sales for the first time.